<DOC>
	<DOCNO>NCT00563173</DOCNO>
	<brief_summary>The purpose study evaluate DNA vaccine CHRONVAC-C® intend future treatment Hepatitis C infection safe tolerate administered HCV infect individual low viral load . In addition capability vaccine induce immune response effect viral load study . In order increase uptake vaccine intra muscular injection combine electroporation , mean brief electric field apply injection site result temporary pore cell membrane allow vaccine enter cell .</brief_summary>
	<brief_title>Phase I/IIa Dose Ranging CHRONVAC-C® Study Chronic HCV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Male female patient 18 65 year age know chronic hepatitis C infection . Genotype 1 infection . Viral load equal le 800.000 IU/mL . BMI le 30 . Considered probable deltoid muscle ( left right ) patient reach vaccination use 12.7 mm cannula injection 15 mm applicator tip electroporation . Written inform consent obtain , copy provide patient . Patient legally competent able communicate effectively study personnel . Patient likely cooperate attend clinic appoint time study . Patient clinically significant concomitant disease HCV medical history discretion investigator . Patient clinically significant finding physical examination , vital sign , ECG clinical laboratory evaluation discretion investigator . Patient clinical biochemical sign cirrhosis . Positive hepatitis B surface antigen ( HBsAg ) . Positive HIV antigen antibody test . Patient ongoing and/or know viral infection HCV require treatment and/or special medical intention . Patient receive previous treatment HCV . Radiation therapy cytotoxic chemotherapeutic agent within 4 week prior first dose study drug . Treatment immunomodulating agent systemic corticosteroid , IL2 , IFNalpha , IFNbeta , IFNgamma within 4 week prior first dose study drug . Treatment NSAID within 10 day first dose study drug . Immunization within 30 day first dose study drug . Patient receive investigational drug product , enrol investigational drug protocol within period 30 day prior receive first dose study drug . Prior treatment DNA therapy . Known allergy towards vaccine . Known abuse alcohol , drug pharmaceutical . History , sign symptoms cardiac disease . Presence implantable pacemaker . Any metal implant within treatment area ( close right and/or leave deltoid muscle ) . Diagnoses serious psychiatric illness may influence study participation . Female patient breast feeding . Female patient clinically sterile ( hysterectomy , tubal ligation postmenopausal ( amenorrhea &gt; 1 year FSH &gt; 30 mU/ml ) OR clinically sterile unwilling use reliable contraception method . Patient positive urine pregnancy test . Male patient unwilling use condom active prevention pregnancy first vaccination 4 month last injection . Patient immediate family investigator site personnel directly affiliate study . Immediate family define spouse , parent , child sibling , whether biologically legally adopt .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>